FDA Approves First Maintenance Therapy for AML FDA Approves First Maintenance Therapy for AML
The FDA has approved an oral formulation of azacitidine for the continued treatment of adults with acute myeloid leukemia (AML) who have achieved initial complete remission.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 3, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Making another run at cancer, S.F. biotech corrects course after clinical trial failure
Even as an early-stage study failed with one drug in 2018, Cleave Therapeutics Inc. were readying a next-generation drug against acute myeloid leukemia. It enrolled the first patient this summer in the new drug's first clinical trial. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 2, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news

Making another run at cancer, S.F. biotech corrects course after clinical trial failure
Even as an early-stage study failed with one drug in 2018, Cleave Therapeutics Inc. were readying a next-generation drug against acute myeloid leukemia. It enrolled the first patient this summer in the new drug's first clinical trial. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 2, 2020 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

FDA Approves Onureg (azacitidine tablets) as Continued Treatment for Adults in First Remission with Acute Myeloid Leukemia
PRINCETON, N.J.--(BUSINESS WIRE) September 1, 2020 --Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Onureg (azacitidine 300 mg tablets, CC-486) for the continued treatment of adult... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 2, 2020 Category: Drugs & Pharmacology Source Type: news

FDA approves Onureg (azacitidine tablets) for acute myeloid leukemia
FDA approved azacitidine tablets (ONUREG ®, Celgene Corporation) for acute myeloid leukemia. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - September 1, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Acute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment
Guidance for Industry: Acute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 17, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Drug Combo Prolongs Survival in Acute Myeloid Leukemia
Findings seen for azacitidine + venetoclax in older patients ineligible for intensive chemotherapy (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - August 13, 2020 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Conference News, Source Type: news

Drug Combo Prolongs Survival in Acute Myeloid Leukemia
THURSDAY, Aug. 13, 2020 -- Overall survival is longer and the incidence of remission is higher among previously untreated, older patients with acute myeloid leukemia (AML) who receive azacitidine plus venetoclax versus azacitidine alone, according... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 13, 2020 Category: Pharmaceuticals Source Type: news

Azacitidine + Venetoclax Combo Benefits Older Patients With AML Azacitidine + Venetoclax Combo Benefits Older Patients With AML
The treatment regimen improved overall survival and remission rates with rapid responses in the tough-to-treat population of older patients with acute myeloid leukemia (AML).Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 12, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

ASH Issues Guidelines on Newly Diagnosed AML in Older Adults
WEDNESDAY, Aug. 12, 2020 -- In evidence-based guidelines issued by the American Society of Hematology and published in the Aug. 11 issue of Blood Advances, recommendations are presented for the management of newly diagnosed acute myeloid leukemia... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 12, 2020 Category: Pharmaceuticals Source Type: news

Combination therapy improves survival outcomes for patients with acute myeloid leukemia
(University of Texas M. D. Anderson Cancer Center) A combination regimen of venetoclax and azacitidine was safe and improved overall survival (OS) over azacitidine alone in certain patients with acute myeloid leukemia (AML), according to the Phase III VIALE-A trial led by The University of Texas MD Anderson Cancer Center. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 12, 2020 Category: International Medicine & Public Health Source Type: news

New study may refine predicted survival outcomes and treatment in younger adults with acute leukemia
(Ohio State University Wexner Medical Center) The findings of a new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute could refine an important set of prognostic and treatment recommendations for younger adult patients with acute myeloid leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 5, 2020 Category: Cancer & Oncology Source Type: news

Large international study pinpoints impact of TP53 gene mutations on blood cancer severity
(Memorial Sloan Kettering Cancer Center) A large international study led by researchers at Memorial Sloan Kettering has immediate clinical relevance for risk assessment and treatment of people with myelodysplastic syndrome and acute myeloid leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 3, 2020 Category: Cancer & Oncology Source Type: news

Huntsman Cancer Institute illuminates potential new treatment in acute myeloid leukemia
(Huntsman Cancer Institute) In a study published in the journal Leukemia, lead author Ami Patel, MD, Huntsman Cancer Institute researcher and assistant professor in the Division of Hematology and Hematologic Malignancies at the University of Utah, showed that factors produced by bone marrow support cells allowed leukemia cells to survive treatment with quizartinib, a type of TKI. When quizartinib was combined with another TKI called dasatinib the alternative survival pathways were shut down, leading to more effective leukemia cell death. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 31, 2020 Category: Cancer & Oncology Source Type: news

Don't Overlook Treating Older Patients With APL, Expert Says Don't Overlook Treating Older Patients With APL, Expert Says
A conversation with Dr Heidi Klepin on why this subtype of acute myeloid leukemia is surprisingly treatable in older patients, if quickly identified.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 17, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

A new nanoconjugate blocks acute myeloid leukemia tumor cells without harming healthy ones
(Universitat Autonoma de Barcelona) The nanoparticle targets only leukemic cells and therefore would reduce the severe adverse effects of current treatments. The receptor for this nanoparticle is expressed in 20 types of cancer and associated with a poor prognosis, so this drug could open a new therapeutic pathway for other tumors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 9, 2020 Category: Cancer & Oncology Source Type: news

Oncotarget: RSK inhibitor BI-D1870 inhibits acute myeloid leukemia cell proliferation
(Impact Journals LLC) The cover for issue 25 of Oncotarget features Figure 8, 'BI-D1870 in combination with vincristine increase metaphase arrest and apoptosis synergistically,' by Chae, et al. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 23, 2020 Category: Cancer & Oncology Source Type: news

Call for caution for using a CAR-T immunotherapy against acute myeloid leukemia
(Josep Carreras Leukaemia Research Institute) Researchers from the Josep Carreras Leukaemia Research Institute prove that the preclinical implementation of Acute Myeloid Leukaemia immunotherapy, based on CD123-redirected CAR T-cells, affects hematopoiesis, blood cells production, and reconstitution. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 17, 2020 Category: Cancer & Oncology Source Type: news

Positive phase III results for Venclexta/Venclyxto combination in acute myeloid leukaemia presented at EHA 2020
Basel, 13 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive results from the phase III VIALE-A study, evaluating Venclexta ®/Venclyxto® (venetoclax) in combination with azacitidine in people with previously untreated acute myeloid leukaemia (AML) who were ineligible for intensive induction chemotherapy. VIALE-A results were featured in the 25th European Hematology Association Virtual Congress Press Briefing on Saturda y 13 June 2020 at 08:30 CEST and will be presented at the congress during the Late-breaking Oral Session (abstract #LB2601) on Sunday 14 June 2020.“We are very pleased to p...
Source: Roche Media News - June 13, 2020 Category: Pharmaceuticals Source Type: news

Positive phase III results for Venclexta/Venclyxto combination in acute myeloid leukaemia presented at EHA 2020
Basel, 13 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive results from the phase III VIALE-A study, evaluating Venclexta ®/Venclyxto® (venetoclax) in combination with azacitidine in people with previously untreated acute myeloid leukaemia (AML) who were ineligible for intensive induction chemotherapy. VIALE-A results were featured in the 25th European Hematology Association Virtual Congress Press Briefing on Saturda y 13 June 2020 at 08:30 CEST and will be presented at the congress during the Late-breaking Oral Session (abstract #LB2601) on Sunday 14 June 2020.“We are very pleased to p...
Source: Roche Investor Update - June 13, 2020 Category: Pharmaceuticals Source Type: news

Leukemia immune profiles predict drug resistance and benefits of immunotherapy
(American Association for the Advancement of Science) By analyzing 442 samples from three groups of children and adults with acute myeloid leukemia (AML), researchers have identified new immune classes of the disease that predict the likelihood of drug resistance and positive responses to immunotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 4, 2020 Category: Cancer & Oncology Source Type: news

$2 million SBIR grant fast-tracks cancer drug platform technology
(Purdue University) A $1,999,998 SBIR Phase I/II grant from the National Institute of Cancer to KinaRx LLC, a Purdue University-affiliated startup, will help fast-track to human trials a novel platform aimed at treating relapse for acute myeloid leukemia and other diseases. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 3, 2020 Category: International Medicine & Public Health Source Type: news

Discovery in human acute myeloid leukemia could provide novel pathway to new treatments
(The Mount Sinai Hospital / Mount Sinai School of Medicine) Researchers at Mount Sinai have discovered that human acute myeloid leukemia (AML) stem cells are dependent on a transcription factor known as RUNX1, potentially providing a new therapeutic target to achieve lasting remissions or even cures for a disease in which medical advances have been limited. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 2, 2020 Category: Cancer & Oncology Source Type: news

Courtney DiNardo, MD, on Need for Improved, Effective Regimens in IDH1-Positive AML
The MD Anderson Cancer Center expert discussed why there is an unmet need for more treatments in patients with IDH1-mutated acute myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - May 31, 2020 Category: Cancer & Oncology Authors: Courtney DiNardo, MD Source Type: news

AMG 330 Appears Safe, Tolerable in Relapsed/Refractory Acute Myeloid Leukemia
The most common, expected, and reversible treatment-emergent adverse event associated with the agent was cytokine release syndrome. (Source: CancerNetwork)
Source: CancerNetwork - May 31, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

Combination therapy well-tolerated and highly effective for patients with IDH1-mutated AML
(University of Texas M. D. Anderson Cancer Center) A combination therapy of ivosenidib (IVO) plus venetoclax (VEN) with or without azacitidine (AZA) was found to be effective against a specific genetic subtype of acute myeloid leukemia (AML) in a Phase Ib/II trial led by researchers at The University of Texas MD Anderson Cancer Center. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 28, 2020 Category: Cancer & Oncology Source Type: news

Genetic Factors in AML With Myelodysplasia-Related Changes Genetic Factors in AML With Myelodysplasia-Related Changes
This study explored the clinical significance of three subcategories of AML-MRC.American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 19, 2020 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Dexrazoxane Preserved Cardiac Function in Children Undergoing Chemotherapy for AML
A study found that dexrazoxane, a cardioprotective drug, preserved cardiac function without compromising overall survival and event-free survival for pediatric patients with acute myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - May 18, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news

Janssen ’s BCMA CAR-T Therapy JNJ-4528 Showed Early, Deep and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma
RARITAN, NJ, May 13, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of JNJ-4528, an investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy in the treatment of patients with relapsed or refractory multiple myeloma. Longer-term follow-up results from the Phase 1b portion of the study (n=29), to be shared in an oral presentation at the American Society of Clinical Oncology (ASCO) Virtual Scientific Program (Abstract #8505), show t...
Source: Johnson and Johnson - May 14, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

AML:'Start as Oncology Patients, but Return With Heart Damage'AML:'Start as Oncology Patients, but Return With Heart Damage '
Children treated for acute myeloid leukemia are often cured of their cancer but return years later with hearts damaged by therapy. Cardioprotection with dexrazoxane could help, say experts.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 12, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Dexrazoxane Preserves Cardiac Function in Pediatric Leukemia
TUESDAY, May 12, 2020 -- For pediatric patients with acute myeloid leukemia (AML), dexrazoxane preserves cardiac function without affecting survival, according to a study published online April 28 in the Journal of Clinical Oncology. Kelly D. Getz,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 12, 2020 Category: Pharmaceuticals Source Type: news

EU Panel OKs Glasdegib for AML & Luspatercept for MDS EU Panel OKs Glasdegib for AML & Luspatercept for MDS
Glasdegib has been recommended for approval in Europe for acute myeloid leukemia, and luspatercept has been recommended for anemia associated with myelodysplastic syndromes.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 1, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

EU Panel OKs Glasdegib for AML and Luspatercept for MDS EU Panel OKs Glasdegib for AML and Luspatercept for MDS
Glasdegib has been recommended for approval in Europe for acute myeloid leukemia, and luspatercept has been recommended for anemia associated with myelodysplastic syndromes.International Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 1, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA Grants Priority Review to CC-486 for the Treatment of Acute Myeloid Leukemia
The FDA granted priority review to a new drug application for CC-486 for the maintenance treatment of adult patients with acute myeloid leukemia based on efficacy and safety results from the pivotal phase III QUAZAR AML-001 study. (Source: CancerNetwork)
Source: CancerNetwork - May 1, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb ’s Application for CC-486 for Maintenance Treatment of Adult Patients in Remission with Acute Myeloid Leukemia
PRINCETON, N.J.--(BUSINESS WIRE) May 1, 2020 --Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for CC-486, an investigational oral hypomethylating agent,... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - May 1, 2020 Category: Drugs & Pharmacology Source Type: news

Smoking Tied to Inferior Survival in Acute Myeloid Leukemia
WEDNESDAY, April 29, 2020 -- Smoking status is an important patient-related prognostic factor for outcome in patients with acute myeloid leukemia (AML) treated with intensive chemotherapy, according to a study published online April 21 in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 29, 2020 Category: Pharmaceuticals Source Type: news

EHA Webinar Addresses Treating AML Patients With COVID-19 EHA Webinar Addresses Treating AML Patients With COVID-19
A hematologist in Italy shared his personal experience regarding COVID-19 and the care of acute myeloid leukemia (AML) patients during a   webinar   hosted by the European Hematology Association.Medscape Medical News (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - April 29, 2020 Category: Pathology Tags: Hematology-Oncology News Source Type: news

Drug prevents severe cardiac events in children undergoing chemotherapy for AML
(Children's Hospital of Philadelphia) The cardioprotective drug dexrazoxane preserved cardiac function in pediatric patients undergoing chemotherapy for acute myeloid leukemia (AML) without compromising overall patient survival and potentially improving it, according to a new study by researchers at Children's Hospital of Philadelphia (CHOP). The results suggest dexrazoxane should be considered for cardioprotection in all pediatric patients undergoing standard chemotherapy for AML. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 28, 2020 Category: Cancer & Oncology Source Type: news

Treatment Approaches in Acute Myeloid Leukemia Treatment Approaches in Acute Myeloid Leukemia
Dr James Foran speaks with Dr David Henry about his preferred treatment algorithm for patients with AML.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 22, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology Article Source Type: news

Three-Drug Combo'Highly Effective' in Acute Myeloid Leukemia Three-Drug Combo'Highly Effective' in Acute Myeloid Leukemia
A new combination of old drugs has shown'unexpectedly'higher response rates in patients with relapsed/refractory acute myeloid leukemia.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 31, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Roche announces Venclexta/Venclyxto combination improved overall survival in people with previously untreated acute myeloid leukaemia
Basel, 23 March 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III VIALE-A study met its dual primary endpoints of overall survival and composite complete remission rate (CR + CRi). Venclexta ®/Venclyxto® (venetoclax) in combination with azacitidine, a hypomethylating agent, showed a statistically significant improvement in overall survival in people with previously untreated acute myeloid leukaemia (AML) who were ineligible for intensive induction chemotherapy, compared to azacitidine alone. Safety for Venclexta/Venclyxto plus azacitidine appeared consistent with the known safety profile ...
Source: Roche Investor Update - March 23, 2020 Category: Pharmaceuticals Source Type: news

Roche announces Venclexta/Venclyxto combination improved overall survival in people with previously untreated acute myeloid leukaemia
Basel, 23 March 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III VIALE-A study met its dual primary endpoints of overall survival and composite complete remission rate (CR + CRi). Venclexta ®/Venclyxto® (venetoclax) in combination with azacitidine, a hypomethylating agent, showed a statistically significant improvement in overall survival in people with previously untreated acute myeloid leukaemia (AML) who were ineligible for intensive induction chemotherapy, compared to azacitidine alone. Safety for Venclexta/Venclyxto plus azacitidine appeared consistent with the known safety profile ...
Source: Roche Media News - March 23, 2020 Category: Pharmaceuticals Source Type: news

Venetoclax with Azacytidine Improved Overall Survival for Patients with AML
Genentech recently announced their phase III study resulted in improved overall survival and composite complete remission rates for patients with previously untreated acute myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - March 23, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news

Oncotarget Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity
(Impact Journals LLC) Oncotarget Volume 11, Issue 11 reported that in this preclinical study, we characterized the binding affinity and selectivity of quizartinib, a small-molecule inhibitor of FLT3, and AC886, the active metabolite of quizartinib, compared with those of other FLT3 inhibitors.Dr. Takeshi Isoyama from Daiichi Sankyo Co., Ltd. said, " FMS like tyrosine kinase 3 (FLT3) is a receptor tyrosine kinase expressed by acute myeloid leukemia (AML) cells in 70% to 90% of patients. " (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 20, 2020 Category: International Medicine & Public Health Source Type: news

Venetoclax and Chemo: A'Step Forward' for Children With r/r AML Venetoclax and Chemo: A'Step Forward' for Children With r/r AML
Adding the targeted therapy to chemotherapy has shown good results in pediatric patients with relapsed or refractory acute myeloid leukemia.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 17, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Use of Post-HSCT Cyclophosphamide Improves Transplantation Outcomes for AML/MDS
Hematopoietic stem cell transplantation (HSCT) with prior use of checkpoint inhibitors was found to be feasible in patients with acute myeloid leukemia and/or myelodysplastic syndromes and the use of post-HSCT cyclophosphamide as graft-versus host disease prophylaxis improves outcomes. (Source: CancerNetwork)
Source: CancerNetwork - March 12, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

€ 2.45 m to investigate leukaemia causes and therapies
(European Molecular Biology Laboratory) The Heidelberg-based LeukoSyStem consortium investigates leukemia stem cells in acute myeloid leukemia. The German Federal Ministry of Education and Research financially supports this collaboration between Heidelberg University Hospital, HI-STEM gGmbH, the German Cancer Research Center   and EMBL. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 11, 2020 Category: International Medicine & Public Health Source Type: news

First-in-human study uses universal donor 'natural killer cells' to treat acute myeloid leukemia
(Ohio State University Wexner Medical Center) A new, phase I clinical trial offered The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) will treat patients with relapsed or refractory acute myeloid leukemia (AML) using a novel universal natural killer cell approach. The trial will be conducted in partnership with Kiadis, a clinical stage biopharmaceutical company. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 27, 2020 Category: International Medicine & Public Health Source Type: news

FDA D.I.S.C.O.: A new drug approval for IDH1 positive relapsed or refractory Acute Myeloid Leukemia
FDA medical oncologists discuss the July 2018 approval of ivosidenib for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 27, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Initial FLAG-Ida Outperforms 7+3 for High-Risk AML Initial FLAG-Ida Outperforms 7+3 for High-Risk AML
A treatment commonly used as a salvage regimen for relapsed/refractory acute myelogenous leukemia (AML) showed better results than did standard treatment when used as initial induction therapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 26, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news